- Oramed Pharmaceuticals (NASDAQ:ORMP +13.9%) says it delivered to the FDA the protocol for phase 2a testing of its oral insulin capsule treating both Type 1 and Type 2 diabetes.
- The protocol was submitted under ORMP's existing investigational new drug application for its ORMD-0801 drug candidate; the double-blind, placebo controlled study, expected to start next month, will be carried out over seven days at an in-patient facility with 24 Type 1 diabetic patients.
Oramed submits phase 2a protocol to FDA for diabetes treatment, +14%
Recommended For You
More Trending News
About ORMP Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ORMP | - | - |
Oramed Pharmaceuticals Inc. |